- Conditions
- Refractory Differentiated Thyroid Gland Carcinoma
- Interventions
- Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging, Questionnaire Administration, Trametinib
- Procedure · Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 307
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 222 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 1,348
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 1,875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 404
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 298 more
- Conditions
- New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
- Interventions
- Anakinra, Tocilizumab, Standard medical treatment
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
- Conditions
- Myelofibrosis
- Interventions
- Selinexor, Placebo, Ruxolitinib
- Drug · Other
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Duarte, California + 31 more
- Conditions
- HPV Vaccination
- Interventions
- HPV vaccine, Inpatient Postpartum HPV Immunization Quality Improvement Program
- Drug · Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 15 Years to 26 Years · Female only
- Enrollment
- 817 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 154
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more
- Conditions
- Healthy
- Interventions
- PF-07081532, Cyclosporine, Itraconazole
- Drug · Device
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Staphylococcal Vaccine
- Interventions
- Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 3,450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 234
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more
- Conditions
- Ovarian Carcinoma
- Interventions
- Sacituzumab govitecan
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Sarcoma, Kaposi, HIV Infections
- Interventions
- Etoposide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2000
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Digestive System Diseases
- Interventions
- Confocal Imaging
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- 0.15 mg PF-06649751, 0.5 mg PF-06649751, 1.5 mg PF-06649751, 1.5 mg PF-06649751 21 Days, 3.0 mg PF-06649751, 5.0 mg PF-06649751, 8.0 mg PF-06649751, 1.5 mg PF-06649751 in healthy Japanese subjects
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
- Procedure · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 275
- States / cities
- Birmingham, Alabama • Clovis, California • Concord, California + 195 more
- Conditions
- HIV Infections
- Interventions
- Methadone hydrochloride, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Pediatric Crohn's Disease
- Interventions
- Methotrexate, Sugar pill (placebo)
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
- Conditions
- Menopausal Women
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 42 Years to 58 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Major Depressive Disorder, Anxiety Disorder
- Interventions
- Ketamine, Midazolam
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Alcohol Use Disorder
- Interventions
- Brief Negotiated Interview (BNI), BNI+facilitated provision of MAUD, Brief Negotiated Interview BNI+facilitated provision of MAUD+CBT4CBT
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Ramucirumab
- Procedure · Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 454
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more
- Conditions
- Traumatic Brain Injury, Ischemic Stroke, Intracerebral Hemorrhage
- Interventions
- Decision Aid
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Worcester, Massachusetts
- Conditions
- Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
- Interventions
- Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization
- Drug · Combination Product
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 11
- States / cities
- San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more
- Conditions
- Anxiety
- Interventions
- Bedside Entertainment and Relaxation Theater (BERT)
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 4 Years to 14 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Congestive Heart Failure, Ventricular Function, Left
- Interventions
- Not listed
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut